Clinical presentation based on mutational status in acute/lymphomatous ATLL
| . | TP53 (n = 7) . | EPI (n = 11) . | None (n = 8) . | P . |
|---|---|---|---|---|
| Age, y | 54 | 54 | 63 | .51 (between groups) |
| WBC | 19.2 | 14.9 | 5.2 | .04 (TP53 vs none) |
| Albumin | 3.4 | 4.1 | 3.5 | .13 (between groups) |
| Corrected calcium | 13.8 | 11.5 | 11.8 | .02 (TP53 vs none) |
| Lactate dehydrogenase | 2022 | 579 | 586 | .20 (between groups) |
| Median OS, d | 160 | 176 | 382 | |
| Progression-free survival, d | 98 | 128 | 240.5 |
| . | TP53 (n = 7) . | EPI (n = 11) . | None (n = 8) . | P . |
|---|---|---|---|---|
| Age, y | 54 | 54 | 63 | .51 (between groups) |
| WBC | 19.2 | 14.9 | 5.2 | .04 (TP53 vs none) |
| Albumin | 3.4 | 4.1 | 3.5 | .13 (between groups) |
| Corrected calcium | 13.8 | 11.5 | 11.8 | .02 (TP53 vs none) |
| Lactate dehydrogenase | 2022 | 579 | 586 | .20 (between groups) |
| Median OS, d | 160 | 176 | 382 | |
| Progression-free survival, d | 98 | 128 | 240.5 |
EPI, any epigenetic mutation.